|
47
|
203
|
1lv1A |
Crystal structure analysis of the non-active site mutant of tethered hiv-1 protease to 2.1a resolution |
|
16
|
99
|
1lzqA |
Crystal structure of the complex of mutant hiv-1 protease (a71v, v82t, i84v) with an ethylenamine peptidomimetic inhibitor boc-phe-psi[ch2ch2nh]-phe-glu-phe-nh2 |
|
17
|
99
|
1mesA |
Hiv-1 mutant (i84v) protease complexed with dmp323 |
|
16
|
99
|
1m0bA |
Hiv-1 protease in complex with an ethyleneamine inhibitor |
|
16
|
99
|
1metA |
Hiv-1 mutant (v82f) protease complexed with dmp323 |
|
15
|
99
|
1merA |
Hiv-1 mutant (i84v) protease complexed with dmp450 |
|
17
|
99
|
1kzkA |
Je-2147-hiv protease complex |
|
14
|
99
|
1kj4A |
Substrate shape determines specificity of recognition recognition for hiv-1 protease: analysis of crystal structures of six substrate complexes |
|
18
|
99
|
1kjhA |
Substrate shape determines specificity of recognition recognition for hiv-1 protease: analysis of crystal structures of six substrate complexes |
|
16
|
99
|
1kjgA |
Substrate shape determines specificity of recognition recognition for hiv-1 protease: analysis of crystal structures of six substrate complexes |
|
18
|
99
|
1kjfA |
Substrate shape determines specificity of recognition recognition for hiv-1 protease: analysis of crystal structures of six substrate complexes |
|
18
|
99
|
1kj7A |
Substrate shape determines specificity of recognition recognition for hiv-1 protease: analysis of crystal structures of six substrate complexes |
|
17
|
99
|
1k2cA |
Combining mutations in hiv-1 protease to understand mechanisms of resistance |
|
17
|
99
|
1k6cA |
Lack of synergy for inhibitors targeting a multi-drug resistant hiv-1 protease |
|
18
|
99
|
1k1uA |
Combining mutations in hiv-1 protease to understand mechanisms of resistance |
|
19
|
99
|
1k2bA |
Combining mutations in hiv-1 protease to understand mechanisms of resistance |
|
17
|
99
|
1k6pA |
Lack of synergy for inhibitors targeting a multi-drug resistant hiv-1 protease |
|
18
|
99
|
1k1tA |
Combining mutations in hiv-1 protease to understand mechanisms of resistance |
|
18
|
99
|
1k6vA |
Lack of synergy for inhibitors targeting a multi-drug resistant hiv-1 protease |
|
19
|
99
|
1k6tA |
Lack of synergy for inhibitors targeting a multi-drug resistant hiv-1 protease |
|
16
|
99
|
1hvkA |
Influence of stereochemistry on activity and binding modes for c2 symmetry-based diol inhibitors of hiv-1 protease |
|
14
|
99
|
1hteA |
X-ray crystallographic studies of a series of penicillin-derived asymmetric inhibitors of hiv-1 protease |
|
17
|
99
|
1hosA |
Inhibition of human immunodeficiency virus-1 protease by a c2-symmetric phosphinate synthesis and crystallographic analysis |
|
16
|
99
|
1hxwA |
Hiv-1 protease dimer complexed with a-84538 |
|
14
|
99
|
1hshA |
Crystal structure at 1.9 angstroms resolution of human immunodeficiency virus (hiv) ii protease complexed with l-735,524, an orally bioavailable inhibitor of the hiv proteases |
|
17
|
99
|
1idaA |
Crystal structures of hiv-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere |
|
17
|
99
|
1hwrA |
Molecular recognition of cyclic urea hiv protease inhibitors |
|
16
|
99
|
1hviA |
Influence of stereochemistry on activity and binding modes for c2 symmetry-based diol inhibitors of hiv-1 protease |
|
13
|
99
|
1hsgA |
Crystal structure at 1.9 angstroms resolution of human immunodeficiency virus (hiv) ii protease complexed with l-735,524, an orally bioavailable inhibitor of the hiv proteases |
|
17
|
99
|
1hvlA |
Influence of stereochemistry on activity and binding modes for c2 symmetry-based diol inhibitors of hiv-1 protease |
|
15
|
99
|
1hvrA |
Rational design of potent, bioavailable, nonpeptide cyclic ureas as hiv protease inhibitors |
|
14
|
99
|
1hsiA |
Crystal structure at 1.9 angstroms resolution of human immunodeficiency virus (hiv) ii protease complexed with l-735,524, an orally bioavailable inhibitor of the hiv proteases |
|
14
|
99
|
1hvsA |
Structural basis of drug resistance for the v82a mutant of hiv-1 protease: backbone flexibility and subsite repacking |
|
16
|
203
|
1hvcA |
Crystal structure of a tethered dimer of hiv-1 protease complexed with an inhibitor |
|
17
|
99
|
1hpxA |
Hiv-1 protease complexed with the inhibitor kni-272 |
|
16
|
99
|
1htgA |
X-ray crystallographic studies of a series of penicillin-derived asymmetric inhibitors of hiv-1 protease |
|
13
|
99
|
1hpoA |
Hiv-1 protease triple mutant/u103265 complex |
|
17
|
99
|
1hxbA |
Hiv-1 proteinase complexed with ro 31-8959 |
|
16
|
99
|
1hvjA |
Influence of stereochemistry on activity and binding modes for c2 symmetry-based diol inhibitors of hiv-1 protease |
|
19
|
99
|
1hpvA |
Crystal structure of hiv-1 protease in complex with vx-478, a potent and orally bioavailable inhibitor of the enzyme |
|
18
|
99
|
1idbA |
Crystal structures of hiv-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere |
|
17
|
99
|
1hivA |
Crystal structure of a complex of hiv-1 protease with a dihydroethylene-containing inhibitor: comparisons with molecular modeling |
|
17
|
99
|
1hbvA |
A check on rational drug design. crystal structure of a complex of hiv-1 protease with a novel gamma-turn mimetic |
|
14
|
99
|
1hefE |
The crystal structures at 2.2 angstroms resolution of hydroxyethylene-based inhibitors bound to human immunodeficiency virus type 1 protease show that the inhibitors are present in two distinct orientations |
|
12
|
99
|
1hhpA |
The three-dimensional structure of the aspartyl protease from the hiv-1 isolate bru |
|
18
|
99
|
1hvhA |
Nonpeptide cyclic cyanoguanidines as hiv protease inhibitors |
|
14
|
99
|
1hegE |
The crystal structures at 2.2 angstroms resolution of hydroxyethylene-based inhibitors bound to human immunodeficiency virus type 1 protease show that the inhibitors are present in two distinct orientations |
|
16
|
99
|
1hihA |
Comparative analysis of the x-ray structures of hiv-1 and hiv-2 proteases in complex with cgp 53820, a novel pseudosymmetric inhibitor |
|
17
|
99
|
1htfA |
X-ray crystallographic studies of a series of penicillin-derived asymmetric inhibitors of hiv-1 protease |
|
19
|
99
|
1hpsA |
Rational design, synthesis and crystallographic analysis of a hydroxyethylene-based hiv-1 protease inhibitor containing a heterocyclic p1'-p2' amide bond isostere |
